American Century Companies Portfolio holdings
American Century Companies, Inc., founded in 1958 by James E. Stowers Jr. as Twentieth Century Mutual Funds and headquartered in Kansas City, Missouri, is a privately held investment management firm renowned for its focus on delivering investment results to clients while supporting medical research. Starting with just $100,000 from 24 shareholders, it rebranded to American Century Investments in 1997 and now manages hundreds of billions in assets across mutual funds, ETFs, and institutional portfolios, emphasizing no-load funds and a client-centric approach. The firm’s unique ownership structure sees over 40% of its profits funneled to the Stowers Institute for Medical Research, which it majority-owns, funding groundbreaking biomedical research, while Nomura Holdings holds a significant minority stake. With a global presence in cities like New York, London, and Hong Kong, and a workforce of around 1,400, American Century blends financial expertise with a mission to improve lives through both wealth creation and scientific advancement.
Top Buys
| 1 |
Pfizer
PFE
|
+$462M |
| 2 |
Colgate-Palmolive
CL
|
+$372M |
| 3 |
Microsoft
MSFT
|
+$331M |
| 4 |
Fidelity National Information Services
FIS
|
+$298M |
| 5 |
Charles Schwab
SCHW
|
+$232M |
Top Sells
| 1 |
WP
Worldpay, Inc.
WP
|
+$300M |
| 2 |
CXO
CONCHO RESOURCES INC.
CXO
|
+$268M |
| 3 |
Medtronic
MDT
|
+$242M |
| 4 |
Intercontinental Exchange
ICE
|
+$203M |
| 5 |
STI
SunTrust Banks, Inc.
STI
|
+$187M |
Sector Composition
| 1 | Financials | 16.66% |
| 2 | Technology | 16% |
| 3 | Healthcare | 15% |
| 4 | Consumer Discretionary | 11.58% |
| 5 | Industrials | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
901
Manhattan Associates
MANH
$13.1B
| $2.92M | ﹤0.01% |
36,219
+1,264
| +4% | +$102K |
|
|
MLPI
902
DELISTED
UBS E-TRACS Alerian MLP Infrastructure ETN
MLPI
| $2.91M | ﹤0.01% |
+139,642
| New | +$2.91M |
|
903
Anika Therapeutics
ANIK
$125M
| $2.91M | ﹤0.01% |
52,958
-15,050
| -22% | -$826K |
|
904
The RMR Group
RMR
$288M
| $2.9M | ﹤0.01% |
63,832
+56,472
| +767% | +$2.57M |
|
905
Universal Electronics
UEIC
$62.3M
| $2.9M | ﹤0.01% |
57,038
+38,296
| +204% | +$1.95M |
|
906
Esperion Therapeutics
ESPR
$573M
| $2.89M | ﹤0.01% |
78,845
+18,596
| +31% | +$682K |
|
907
Toro Company
TTC
$7.76B
| $2.87M | ﹤0.01% |
39,214
-6,842
| -15% | -$501K |
|
|
CVET
908
DELISTED
Covetrus, Inc. Common Stock
CVET
| $2.87M | ﹤0.01% |
241,508
-1,866,595
| -89% | -$22.2M |
|
909
Autodesk
ADSK
$68B
| $2.86M | ﹤0.01% |
19,382
-624,868
| -97% | -$92.3M |
|
910
Quaker Houghton
KWR
$2.46B
| $2.86M | ﹤0.01% |
+18,107
| New | +$2.86M |
|
911
Ironwood Pharmaceuticals
IRWD
$213M
| $2.85M | ﹤0.01% |
331,912
+42,211
| +15% | +$362K |
|
912
Elastic
ESTC
$9.3B
| $2.84M | ﹤0.01% |
34,523
-5,340
| -13% | -$440K |
|
913
Ultragenyx Pharmaceutical
RARE
$2.92B
| $2.82M | ﹤0.01% |
65,842
+2,947
| +5% | +$126K |
|
914
Vanda Pharmaceuticals
VNDA
$266M
| $2.8M | ﹤0.01% |
+210,540
| New | +$2.8M |
|
915
Insperity
NSP
$1.99B
| $2.78M | ﹤0.01% |
28,197
+1,742
| +7% | +$172K |
|
|
AIMT
916
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $2.78M | ﹤0.01% |
132,793
-27,638
| -17% | -$579K |
|
917
Charter Communications
CHTR
$36B
| $2.78M | ﹤0.01% |
6,737
+2,942
| +78% | +$1.21M |
|
|
OPTN
918
DELISTED
OptiNose
OPTN
| $2.77M | ﹤0.01% |
26,420
+6,204
| +31% | +$651K |
|
919
Rollins
ROL
$27.8B
| $2.76M | ﹤0.01% |
121,509
-3,462
| -3% | -$78.6K |
|
920
Veracyte
VCYT
$2.43B
| $2.74M | ﹤0.01% |
114,057
+11,395
| +11% | +$273K |
|
921
Enanta Pharmaceuticals
ENTA
$177M
| $2.73M | ﹤0.01% |
+45,504
| New | +$2.73M |
|
922
AES
AES
$9.17B
| $2.73M | ﹤0.01% |
166,860
-318,758
| -66% | -$5.21M |
|
923
Perdoceo Education
PRDO
$2.26B
| $2.71M | ﹤0.01% |
170,825
+78,146
| +84% | +$1.24M |
|
924
Voyager Therapeutics
VYGR
$232M
| $2.69M | ﹤0.01% |
156,234
+25,103
| +19% | +$432K |
|
|
SIVB
925
DELISTED
SVB Financial Group
SIVB
| $2.67M | ﹤0.01% |
12,772
+4,606
| +56% | +$963K |
|